Top Ranked Growth Stocks to Buy for July 22nd

In this article:

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, July 22nd:

eBay Inc. (EBAY): This commerce platforms operator, which carries a Zacks Rank #2 (Buy), has witnessed the Zacks Consensus Estimate for its current year earnings increasing 1.1% over the last 60 days.

eBay Inc. Price and Consensus

eBay Inc. Price and Consensus
eBay Inc. Price and Consensus

eBay Inc. price-consensus-chart | eBay Inc. Quote

eBay has a PEG ratio of 1.57 compared with 2.21 for the industry. The company possesses a Growth Score of B.

eBay Inc. PEG Ratio (TTM)

eBay Inc. PEG Ratio (TTM)
eBay Inc. PEG Ratio (TTM)

eBay Inc. peg-ratio-ttm | eBay Inc. Quote

Merck & Co., Inc. (MRK):This healthcare solutions provider, which carries a Zacks Rank #2, has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.4% over the last 60 days.

Merck & Co., Inc. Price and Consensus

Merck & Co., Inc. Price and Consensus
Merck & Co., Inc. Price and Consensus

Merck & Co., Inc. price-consensus-chart | Merck & Co., Inc. Quote

Merck has a PEG ratio of 1.73, compared with 1.92 for the industry. The company possesses a Growth Score of B.

Merck & Co., Inc. PEG Ratio (TTM)

Merck & Co., Inc. PEG Ratio (TTM)
Merck & Co., Inc. PEG Ratio (TTM)

Merck & Co., Inc. peg-ratio-ttm | Merck & Co., Inc. Quote

Magellan Health, Inc. (MGLN): This healthcare management services provider, which carries a Zacks Rank #2, has witnessed the Zacks Consensus Estimate for its current year earnings increasing 2% over the last 60 days.

Magellan Health, Inc. Price and Consensus

Magellan Health, Inc. Price and Consensus
Magellan Health, Inc. Price and Consensus

Magellan Health, Inc. price-consensus-chart | Magellan Health, Inc. Quote

Magellan Health has a PEG ratio of 0.73, compared with 1.35 for the industry. The company possesses a Growth Score of A.

Magellan Health, Inc. PEG Ratio (TTM)

Magellan Health, Inc. PEG Ratio (TTM)
Magellan Health, Inc. PEG Ratio (TTM)

Magellan Health, Inc. peg-ratio-ttm | Magellan Health, Inc. Quote

AmerisourceBergen Corporation (ABC): This pharmaceutical products distributor, which carries a Zacks Rank #2, has witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.4% over the last 60 days.

AmerisourceBergen Corporation Price and Consensus

AmerisourceBergen Corporation Price and Consensus
AmerisourceBergen Corporation Price and Consensus

AmerisourceBergen Corporation price-consensus-chart | AmerisourceBergen Corporation Quote

AmerisourceBergen has a PEG ratio of 1.67, compared with 1.75 for the industry. The company possesses a Growth Score of A.

AmerisourceBergen Corporation PEG Ratio (TTM)

AmerisourceBergen Corporation PEG Ratio (TTM)
AmerisourceBergen Corporation PEG Ratio (TTM)

AmerisourceBergen Corporation peg-ratio-ttm | AmerisourceBergen Corporation Quote

See the full list of top ranked stocks here.

Learn more about the Growth score and how it is calculated here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Merck & Co., Inc. (MRK) : Free Stock Analysis Report
 
Magellan Health, Inc. (MGLN) : Free Stock Analysis Report
 
eBay Inc. (EBAY) : Free Stock Analysis Report
 
AmerisourceBergen Corporation (ABC) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Advertisement